Latest Product Launch News

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AoFrio Limited has successfully closed a renounceable pro-rata rights issue, securing NZ$4.428 million to fund its push into US and European markets and advance AI-driven innovations in cold drink equipment.

Osteopore Limited has completed another incremental drawdown of A$250,000 on the second tranche of its redeemable convertible notes, continuing its steady funding progress under a A$20 million subscription agreement with Advance Opportunities Fund.

ECS Botanics has commenced commercial sales of Gelonoidz #20, its first Australian-grown Terphogz cultivar, marking a key step in expanding its premium medicinal cannabis portfolio with plans for more cultivars in FY27.

The a2 Milk Company has clinched final Chinese regulatory approval to rebrand infant formula products under its flagship a2™ label, completing a pivotal acquisition step. The company plans to launch these products later in 2026 and is poised to declare a $300 million special dividend.

Peak Processing has reported three consecutive months of positive EBITDA and raised its Q4 FY26 beverage production guidance to approximately 1.6 million units, surpassing earlier estimates.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

CleanSpace Holdings has achieved a major regulatory milestone with European EN 12941 certification for its new AGILE loose-fitting PAPR, positioning the company for growth in its largest market and preparing for imminent Australian approval.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.

AoFrio Limited has initiated a 1-for-7 renounceable rights offer at NZ$0.07 per share aiming to raise nearly NZ$5 million. This follows a recent $4.56 million placement and supports an aggressive growth strategy targeting $300 million revenue by 2030.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.